Keyphrases
5-HT1A
100%
5-HT1A Agonist
14%
5-HT1A Partial Agonist
14%
5-HT1A Receptor
14%
5-HT2A Agonists
28%
5-HT2A Receptor
14%
Acute Administration
14%
Agonism
100%
Antagonism
28%
Antipsychotics
28%
Atypical Antipsychotics
100%
Cognitive Impairment
28%
D2 Antagonist
14%
Dopamine D2 Antagonist
14%
Dopamine D2 Receptor (DRD2)
100%
Drug Effects
100%
Effective Dose
14%
Efflux
14%
Haloperidol
28%
Inverse Agonism
14%
Lurasidone
14%
N-methyl-D-aspartate Receptor (NMDAR)
14%
Novel Object Recognition
100%
Phencyclidine
100%
Pimavanserin
14%
Prevention Model
14%
Receptor Antagonism
100%
Receptor Antagonist
14%
Schizophrenia
28%
Serotonin 2A Receptor (5-HT2AR)
100%
Serotonin 5-HT
100%
Signaling Cascades
14%
Subchronic Administration
14%
Tandospirone
14%
Triple Combination
14%
Typical Antipsychotics
28%
Pharmacology, Toxicology and Pharmaceutical Science
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
50%
Antipsychotic
50%
Atypical Antipsychotics
100%
Cognitive Defect
50%
Dextro Aspartic Acid
25%
Dopamine 2 Receptor Blocking Agent
25%
Dopamine Receptor D2
100%
Effusion
25%
Inverse Agonist
50%
Lurasidone
25%
Methyldienolone
25%
Partial Agonist
25%
Phencyclidine
100%
Pimavanserin
25%
Receptor
75%
Receptor Antagonist
25%
Serotonin
100%
Serotonin 1A Agonist
25%
Tandospirone
25%
Typical Antipsychotic
50%
Neuroscience
5-HT1A Agonists
16%
5-HT1A Receptor
16%
5-HT2A Receptor
33%
Agonist
16%
Atypical Antipsychotic
100%
Cognitive Disorders
33%
D2 Antagonists
33%
Dementia Praecox
33%
Dextro Aspartic Acid
16%
Dopamine Receptor D2
100%
Haloperidol
33%
In Vivo
16%
Inverse Agonism
16%
Inverse Agonist
33%
Lurasidone
16%
Methyldienolone
16%
Phencyclidine
100%
Pimavanserin
16%
Receptor Antagonist
16%
Serotonin
100%
Tandospirone
16%
Typical Antipsychotic
100%